Izotropic (TSE:IZO) has released an update.
Izotropic Corporation is set to launch IzoView, a breast CT imaging system designed for patients with dense breast tissue, in the U.S and EU markets. The company is charting a regulatory course to position IzoView as an adjunct diagnostic tool, intending to streamline market entry with a focused clinical study. This strategy aims to provide quicker access to innovative breast cancer diagnostics for women at higher risk due to breast density.
For further insights into TSE:IZO stock, check out TipRanks’ Stock Analysis page.
